^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:alrizomadlin (APG-115) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    IASLC-WCLC 2020
    Title:

    MA01.10 - MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations

    Published date:
    01/12/2021
    Excerpt:
    APG-115 is more effective in inhibiting cell proliferation and tumor growth in STK11-mutant NSCLC cells and xenograft models, respectively, in comparison with the wild-type counterparts